AUP Archives - BioTuesdays

Developments

FDA approves Aurinia’s LUPKYNIS for lupus nephritis

The FDA approved Aurinia Pharmaceuticals’ (NASDAQ:AUPH; TSX:AUP) LUPKYNIS (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active lupus nephritis. LUPKYNIS is...

January 25, 2021

Developments

FDA accepts Aurinia NDA for voclosporin; agrees to priority review

The FDA accepted for priority review Aurinia Pharmaceuticals’ (NASDAQ:AUPH; TSX:AUP) NDA for voclosporin for the treatment of lupus nephritis (LN). The NDA for voclosporin is based on the Phase 3 AURORA and Phase 2 AURA...

July 22, 2020

Developments

Aurinia posts positive Phase 3 voclosporin data in lupus nephritis trial

Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP) reported positive efficacy and safety results from its AURORA Phase 3 trial of voclosporin, in combination with mycophenolate (MMF) and low-dose corticosteroids, in the...

December 4, 2019

Executive Moves

Aurinia Pharma names Peter Greenleaf as CEO; George Milne Jr. as chairman

Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP) appointed Peter Greenleaf as CEO, and George Milne Jr. as chairman of the board.

April 12, 2019

Feature

Lupus Foundation puzzled by negative reaction to Aurinia data

By Len Zehr As president and CEO of The Lupus Foundation of America (LFA), a role she has held for 15 years, Sandra Raymond is an outspoken advocate for the plight of lupus patients. She has worked with the board of...

September 6, 2016

Feature

Aurinia to begin lupus nephritis trial at end of April

By Len Zehr Fresh from a US$52-million private placement, Aurinia Pharmaceuticals (TSX-V:AUP) hopes to treat its first lupus patient at the end of April in a Phase 2b clinical trial with its voclosporin...

April 15, 2014

Feature

Aurinia readies Phase 2b trial in lupus nephritis

By Len Zehr Aurinia Pharmaceuticals (TSX-V:AUP) is preparing to begin a Phase 2b clinical trial in the first quarter of 2014 with its voclosporin immunosuppressant in combination with CellCept, the standard of care for...

November 19, 2013

Tag - AUP

FDA approves Aurinia’s LUPKYNIS for lupus nephritis

FDA accepts Aurinia NDA for voclosporin; agrees to priority review

Aurinia posts positive Phase 3 voclosporin data in lupus nephritis trial

Aurinia Pharma names Peter Greenleaf as CEO; George Milne Jr. as chairman

Lupus Foundation puzzled by negative reaction to Aurinia data

Aurinia to begin lupus nephritis trial at end of April

Aurinia readies Phase 2b trial in lupus nephritis

General

More